Navigation Links
VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration
Date:6/7/2011

about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials.  Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.  The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions.  Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide.  Bayer HealthCare has a global workforce of 55.700 employees and is represented in more than 100 countries.  Find more information at www.bayerhealthcare.com.

Regeneron Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future financial performance of Regeneron, and actual events or results may differ materially from these forward-looking statements.  These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
3. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
4. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
5. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
6. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
7. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
8. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
11. Vemurafenib New Drug Application Submitted to FDA for Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014  Iliad Neurosciences, Inc., a company focused ... treating Autism Spectrum Disorders (ASD) announced today that it ... Research Foundation for The State University of New York. ... new biomarker to identify an abnormality in folate transport ... biomarker is expected to be available for research use ...
(Date:9/18/2014)... , September 18, 2014 ... audience, has updated the incredibly successful Serialisation Countdown calendar ... interactive PDF, available at pharmaserialisation.com shows the ... which they will be coming into force. ... longer a matter of "if", but "when" they will ...
(Date:9/18/2014)... , Sept. 18, 2014  Zacks.com announces the ... day the Zacks Equity Research analysts discuss the latest ... Stocks recently featured in the blog include the Avanir Pharmaceuticals ... (Nasdaq: NPSP - Free Report ), Orexigen (Nasdaq: ... MDVN - Free Report ) and Gilead (Nasdaq: ...
Breaking Medicine Technology:Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 2Iliad Neurosciences, Inc. enters into an Exclusive License Agreement with The Research Foundation for The State University of New York 3Pharma IQ Displays Worldwide Serialisation Deadlines in their 2014 - 2018 Countdown Calendar 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 2The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 3The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 4The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 5The Zacks Analyst Blog Highlights: Avanir Pharmaceuticals, NPS Pharmaceuticals, Orexigen, Medivation and Gilead 6
... 14, 2011 Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a ... (IVD) cancer tests, today announced financial results for its ... for the third quarter ended September 30, 2011 were ... September 30, 2010.  For the nine months ended September ...
... Corporation (NASDAQ: LMNX ) today announced ... at the Defense Threat Reduction Agency,s (DTRA) 2011 ... Conference, which takes place November 14-16, 2011 in ... During the conference, Dr. Altman will present ...
Cached Medicine Technology:Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 2Radient Pharmaceuticals Announces FY 2011 Third Quarter Results 3Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 2Luminex Corporation Vice President of Biodefense to Speak at DTRA'S 2011 CBD S&T Conference 3
(Date:9/18/2014)... proven it true: exercise is good for you. But ... exercise may have an added benefit for cancer patients ... model of melanoma, found that combining exercise with chemotherapy ... Libonati, an associate professor in the School of Nursing ... Nursing Research, was the senior author on the study, ...
(Date:9/18/2014)... NJ (PRWEB) September 18, 2014 ... firm, announced today that President and co-founder John ... Journal’s Innovation Award Winners for 2014, recognizing the ... him as an emerging executive of the year. ... care and life sciences that continue to shape ...
(Date:9/18/2014)... 2014 Ben Quirk, CEO of Quirk ... Leadership Award by the Savannah Science Seminar in recognition ... throughout the nation and especially in Savannah. , “I ... Ben. “The Savannah Science Seminar is an amazing program ... generations have gone through the program,” he added. Eleventh ...
(Date:9/18/2014)... international scientists have developed a new method to study ... , The Wildlife Conservation Society (WCS)-led research, published today ... describes the use of fecal samples from wild great ... to the virus. This represents a new tool for ... the way Ebola virus is studied and improve our ...
(Date:9/18/2014)... 2014) The National Institutes of Health (NIH) recently ... $1.3 million grant to the Los Angeles Biomedical Research ... development of a vaccine to protect patients from the ... aureus (MRSA). , The National Institute of ... the grant to LA BioMed infectious disease specialists John ...
Breaking Medicine News(10 mins):Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2Health News:Quirk Awarded the Alex Ormond, Jr. Leadership Award by the Savannah Science Seminar 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:LA BioMed receives NIH grant to study vaccine for hospital-acquired infections 2
... joined hands today to boost efforts by governments in ... ,Headed by C Rangarajan, Chairman of the ... independent commission on AIDS in Asia and the Pacific ... of AIDS in the region and its medium- and ...
... an important ingredient in magic mushrooms is capable of ... addictions. ,Researchers at Johns Hopkins University ... element in mushrooms is capable of instilling a deep ... for those patients who have a huge psychological baggage ...
... about 1,500 medical professionals are available throughout the country ... in India // , President of Madras ENT Rearch ... ,Most of these professionals were concentrated in major ... said at a press conference prior to the inauguration ...
... reported in the United Kingdom, asthmatics will witness almost ... months of completely// staying off cigarettes. ... lung function seen after smoking cessation was clinically significant. ... the harmful effects of smoking on the airways in ...
... to invest more money in mental health, to bridge the ... , Although the new national mental health plan provided a ... short of the escalating expenditure, said John Mendoza, the chief ... ,Mr. Mendoza said that only 40 per cent ...
... the University of Vermont say that drinking cherry juice may ... number of antioxidant// and anti-inflammatory compounds that can deal with ... The British Journal of Sports Medicine, researchers said that men ... levels of inflammatory markers in their blood. The study examined ...
Cached Medicine News:
Electric high speed system....
... High Performance Instrument System was ... for increased power of the ... It provides 60% more torque ... easily handle the most demanding ...
The XK-95 High Speed Drill System sets new technological and performance standards for surgical drill systems....
... Platinum is a compact and quiet, ... at 120 psi/8 bar, it provides ... size with noticeable noise reduction. A ... with an enhanced ergonomic handpiece to ...
Medicine Products: